First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

Table 2 Univariate and multivariate analysis for progression-free survival to first-generation TKI therapy

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P ^†	HR (95% CI)	P ^†
Sex
(Female/male)	1.061 (0.919–1.224)	0.420
Age
(< 60/≥ 60)	1.319 (0.987–1.763)	0.061
Smoking status
(Smoker/nonsmoker/unknown)	0.726 (0.518–1.018)	0.063
Tumour status
(Recurrence/initial IIIb–IV)	0.721 (0.560–0.926)	0.011	0.706 (0.548–0.909)	0.007
ECOG PS
(0–1/2–4)	1.438 (0.872–2.372)	0.154
Pathology
(Non-adeno/adeno)	4.175 (2.113–8.250)	0.001	5.472 (2.623–11.417)	0.001
Timing of TKI
(1/≥ 2)	0.643 (0.480–0.862)	0.003	0.610 (0.452–0.823)	0.001
EGFR mutation status
(Compound/single)	1.883 (1.404–2.526)	0.001	1.981 (1.466–2.676)	0.001
TKI selection
(Gefitinib/erlotinib/icotinib)	0.978 (0.819–1.167)	0.806

ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, CI confidence interval
^†All variables of different subgroups were compared with the single common mutation group; P < 0.05 was defined as significantly different

ISSN: 2523-3548